Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) represents a typical wnt/β-catenin pathway-activated hepatocellular carcinoma

Kathryn Effendi, Ken Yamazaki, Mariko Fukuma, Michiie Sakamoto

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common and most frequently lethal cancers worldwide. Although many advances have been made in the analysis of multistage hepatocarcinogenesis, we still lack information to guide adequate clinical management options for HCC. A large number of genetic alterations occur during hepatocarcinogenesis, and many genetic studies have indicated that one of the most frequently mutated oncogenes found in HCC is β-catenin. Summary: Molecular subclassification of HCC based on gene expression signatures has identified a typical hepatocyte-like subclass of HCC harboring β-catenin mutations; this subclass is characterized by better histological differentiation and a less aggressive nature. We previously identified overexpression of the leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), also known as GPR49, in HCC with β-catenin mutations. LGR5 has been indicated as one of the downstream target genes of the Wnt signaling pathway; however, the functional role of LGR5 in cancer is largely unknown. We demonstrated that HCC cells transfected with LGR5 exhibited higher colony forming activity and were more resistant to a cytotoxic drug than the control HCC cells were. Overexpression of LGR5 also retarded cell migration. LGR5-transfected HCC cells formed nodule-type tumors in the livers of immunodeficient mice, whereas control cells formed more invasive tumors. Results of our recent research suggest that aberrant expression of LGR5 could regulate the epithelial cell phenotype and promotes HCC cell survival. HCC cells overexpressing LGR5 seem to represent a typical phenotype of a less aggressive HCC. Key messages: Recent efforts on the molecular classification of HCC have led us to new strategies for dealing with HCC. These specific signatures may predict the risk of recurrence or the patient survival rate, which affect the outlook and may suggest treatment strategies for HCC patients.

Original languageEnglish
Pages (from-to)451-457
Number of pages7
JournalLiver Cancer
Volume3
Issue number3-4
DOIs
Publication statusPublished - 2014 Apr 16

Fingerprint

Catenins
Wnt Signaling Pathway
G-Protein-Coupled Receptors
Leucine
Hepatocellular Carcinoma
Neoplasms
Phenotype
Mutation
Drug and Narcotic Control
Oncogenes
Transcriptome

Keywords

  • HCC molecular subclassification
  • HCC typical phenotype
  • LGR5
  • LGR5-overexpressing cells
  • WNT/β-catenin

ASJC Scopus subject areas

  • Hepatology
  • Oncology

Cite this

Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) represents a typical wnt/β-catenin pathway-activated hepatocellular carcinoma. / Effendi, Kathryn; Yamazaki, Ken; Fukuma, Mariko; Sakamoto, Michiie.

In: Liver Cancer, Vol. 3, No. 3-4, 16.04.2014, p. 451-457.

Research output: Contribution to journalReview article

@article{d37b92aa9c6543829c33cfe6bdf144e4,
title = "Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) represents a typical wnt/β-catenin pathway-activated hepatocellular carcinoma",
abstract = "Background: Hepatocellular carcinoma (HCC) is one of the most common and most frequently lethal cancers worldwide. Although many advances have been made in the analysis of multistage hepatocarcinogenesis, we still lack information to guide adequate clinical management options for HCC. A large number of genetic alterations occur during hepatocarcinogenesis, and many genetic studies have indicated that one of the most frequently mutated oncogenes found in HCC is β-catenin. Summary: Molecular subclassification of HCC based on gene expression signatures has identified a typical hepatocyte-like subclass of HCC harboring β-catenin mutations; this subclass is characterized by better histological differentiation and a less aggressive nature. We previously identified overexpression of the leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), also known as GPR49, in HCC with β-catenin mutations. LGR5 has been indicated as one of the downstream target genes of the Wnt signaling pathway; however, the functional role of LGR5 in cancer is largely unknown. We demonstrated that HCC cells transfected with LGR5 exhibited higher colony forming activity and were more resistant to a cytotoxic drug than the control HCC cells were. Overexpression of LGR5 also retarded cell migration. LGR5-transfected HCC cells formed nodule-type tumors in the livers of immunodeficient mice, whereas control cells formed more invasive tumors. Results of our recent research suggest that aberrant expression of LGR5 could regulate the epithelial cell phenotype and promotes HCC cell survival. HCC cells overexpressing LGR5 seem to represent a typical phenotype of a less aggressive HCC. Key messages: Recent efforts on the molecular classification of HCC have led us to new strategies for dealing with HCC. These specific signatures may predict the risk of recurrence or the patient survival rate, which affect the outlook and may suggest treatment strategies for HCC patients.",
keywords = "HCC molecular subclassification, HCC typical phenotype, LGR5, LGR5-overexpressing cells, WNT/β-catenin",
author = "Kathryn Effendi and Ken Yamazaki and Mariko Fukuma and Michiie Sakamoto",
year = "2014",
month = "4",
day = "16",
doi = "10.1159/000343873",
language = "English",
volume = "3",
pages = "451--457",
journal = "Liver Cancer",
issn = "2235-1795",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) represents a typical wnt/β-catenin pathway-activated hepatocellular carcinoma

AU - Effendi, Kathryn

AU - Yamazaki, Ken

AU - Fukuma, Mariko

AU - Sakamoto, Michiie

PY - 2014/4/16

Y1 - 2014/4/16

N2 - Background: Hepatocellular carcinoma (HCC) is one of the most common and most frequently lethal cancers worldwide. Although many advances have been made in the analysis of multistage hepatocarcinogenesis, we still lack information to guide adequate clinical management options for HCC. A large number of genetic alterations occur during hepatocarcinogenesis, and many genetic studies have indicated that one of the most frequently mutated oncogenes found in HCC is β-catenin. Summary: Molecular subclassification of HCC based on gene expression signatures has identified a typical hepatocyte-like subclass of HCC harboring β-catenin mutations; this subclass is characterized by better histological differentiation and a less aggressive nature. We previously identified overexpression of the leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), also known as GPR49, in HCC with β-catenin mutations. LGR5 has been indicated as one of the downstream target genes of the Wnt signaling pathway; however, the functional role of LGR5 in cancer is largely unknown. We demonstrated that HCC cells transfected with LGR5 exhibited higher colony forming activity and were more resistant to a cytotoxic drug than the control HCC cells were. Overexpression of LGR5 also retarded cell migration. LGR5-transfected HCC cells formed nodule-type tumors in the livers of immunodeficient mice, whereas control cells formed more invasive tumors. Results of our recent research suggest that aberrant expression of LGR5 could regulate the epithelial cell phenotype and promotes HCC cell survival. HCC cells overexpressing LGR5 seem to represent a typical phenotype of a less aggressive HCC. Key messages: Recent efforts on the molecular classification of HCC have led us to new strategies for dealing with HCC. These specific signatures may predict the risk of recurrence or the patient survival rate, which affect the outlook and may suggest treatment strategies for HCC patients.

AB - Background: Hepatocellular carcinoma (HCC) is one of the most common and most frequently lethal cancers worldwide. Although many advances have been made in the analysis of multistage hepatocarcinogenesis, we still lack information to guide adequate clinical management options for HCC. A large number of genetic alterations occur during hepatocarcinogenesis, and many genetic studies have indicated that one of the most frequently mutated oncogenes found in HCC is β-catenin. Summary: Molecular subclassification of HCC based on gene expression signatures has identified a typical hepatocyte-like subclass of HCC harboring β-catenin mutations; this subclass is characterized by better histological differentiation and a less aggressive nature. We previously identified overexpression of the leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), also known as GPR49, in HCC with β-catenin mutations. LGR5 has been indicated as one of the downstream target genes of the Wnt signaling pathway; however, the functional role of LGR5 in cancer is largely unknown. We demonstrated that HCC cells transfected with LGR5 exhibited higher colony forming activity and were more resistant to a cytotoxic drug than the control HCC cells were. Overexpression of LGR5 also retarded cell migration. LGR5-transfected HCC cells formed nodule-type tumors in the livers of immunodeficient mice, whereas control cells formed more invasive tumors. Results of our recent research suggest that aberrant expression of LGR5 could regulate the epithelial cell phenotype and promotes HCC cell survival. HCC cells overexpressing LGR5 seem to represent a typical phenotype of a less aggressive HCC. Key messages: Recent efforts on the molecular classification of HCC have led us to new strategies for dealing with HCC. These specific signatures may predict the risk of recurrence or the patient survival rate, which affect the outlook and may suggest treatment strategies for HCC patients.

KW - HCC molecular subclassification

KW - HCC typical phenotype

KW - LGR5

KW - LGR5-overexpressing cells

KW - WNT/β-catenin

UR - http://www.scopus.com/inward/record.url?scp=84945139219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945139219&partnerID=8YFLogxK

U2 - 10.1159/000343873

DO - 10.1159/000343873

M3 - Review article

AN - SCOPUS:84945139219

VL - 3

SP - 451

EP - 457

JO - Liver Cancer

JF - Liver Cancer

SN - 2235-1795

IS - 3-4

ER -